Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report) saw a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 112,900 shares, a drop of 18.3% from the March 31st total of 138,200 shares. Currently, 5.4% of the company’s shares are short sold. Based on an average daily volume of 264,300 shares, the days-to-cover ratio is currently 0.4 days.
Salarius Pharmaceuticals Price Performance
Shares of NASDAQ:SLRX opened at $0.70 on Friday. The stock’s 50-day moving average is $0.83 and its 200 day moving average is $1.43. The company has a market cap of $1.48 million, a PE ratio of -0.09 and a beta of 0.42. Salarius Pharmaceuticals has a 1 year low of $0.45 and a 1 year high of $7.20.
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) last announced its earnings results on Friday, March 21st. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($2.31) by $1.65.
Salarius Pharmaceuticals Company Profile
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Featured Stories
- Five stocks we like better than Salarius Pharmaceuticals
- Stock Market Sectors: What Are They and How Many Are There?
- Magnificent 7 Stocks Send a Dire Warning to Markets
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Why Spotify Stock Still Has Room to Run in 2025
- How to Profit From Growth Investing
- Buy the Dip: Top Tech Stocks Analysts Say Are Undervalued
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
